Overview
KYTX market data
Price History
KYTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.01 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -411.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.80 – $13.67 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $479.7M · P/B 2.31.
Company News
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) EstimateBenzinga · Aug 11, 2026, 8:18 PM
Kyverna Therapeutics shares are trading higher after the company and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, autologous CD19-directed CAR T-cell therapy.Benzinga · Jul 27, 2026, 2:03 PM
Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell TherapyBenzinga · Jul 27, 2026, 12:04 PM
8-K filing — Kyverna Therapeutics, Inc. (KYTX)SEC EDGAR · Jul 27, 2026, 12:00 PM
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsightGlobenewswire Inc · Jun 10, 2026, 5:15 PM
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?The Motley Fool · Jun 8, 2026, 7:15 PM
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price TargetBenzinga · Jun 3, 2026, 4:20 PM
Kyverna Therapeutics Appoints Greg Martini As CFOBenzinga · May 18, 2026, 12:10 PM